

SIDDIK SARKAR

Durgapur, Daral hat, Dist: Dakshin Dinajpur, West Bengal , PIN-733127
Mobile: +91-9474333344, E-mail: siddikiitkgp@gmail.com

Objective:

I am seeking to undergo as a researcher in the field of Cancer Biology and to study its causes and remedies at molecular level. It will develop my skills and hone it under the environment of excellence and creativity.

Education:

Ph.D., Cancer Biology, Indian Institute of Technology (IIT) Kharagpur, 2006-2010

Dissertation: **The molecular effect of ZD6474, a dual tyrosine kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor on breast cancer progression and treatment.**

M.Sc., Biotechnology, Indian Institute of Technology (IIT) Roorkee, 2002-2004

B.Sc. (Hons.), Biochemistry, Sri Venkateswara College, University of Delhi, 1999-2002

Achievements:

- Won first prize in poster presentation in International Conference “Emerging Trends in Biological Sciences”, KIIT Bhubaneswar, Bhubaneswar, India. Oct 2008.
- Won first prize in National Level Technical Festival “Cognizance-2004” held at IIT Roorkee for model making competition “The Motifs”.
- Won first prize in National Level Technical Festival “Cognizance-2004” held at IIT Roorkee for Poster making competition.
- Awarded CSIR-JRF (Council of Scientific and Industrial Research- Junior Research Scholar)
- Screened for SPM (Shyama Prasad Mukherjee) award on the merit basis for NET Examination (June 2004)
- Awarded scholarship for Masters programme in Biotechnology on Merit basis sponsored by DBT (Department of Biotechnology, India)

Publications:

- Sarkar, S., and Mandal, M. (2009). Growth Factor Receptors and Apoptosis Regulators: Signaling Pathways, Prognosis, Chemosensitivity and Treatment Outcomes of Breast Cancer. *Breast Cancer: Basic and Clinical Research* 3,47-60.
- Sarkar, S., Mazumdar, A., Dash, R., Sarkar, D., Fisher, P. B., and Mandal, M. (2010). ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. *Cancer Biol Ther* 9(8), 592-603.
- Sarkar, S., Mazumdar, A., Dash, R., Sarkar, D., Fisher, P. B., and Mandal, M. (2011). ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. *J Cell Physiol*. 226(2), 375-84.
- Sethi, K., Sarkar, S., Das, S., Mohanty, B., and Mandal, M. (2010). Biomarkers for the Diagnosis of Thyroid Cancer. *J Exp Ther Oncol* 8(4), 341-52.
- Mandal, S. M., Dey, S., Mandal, M., Sarkar, S., Maria-Neto, S., and Franco, O. L. (2009). Identification and structural insights of three novel antimicrobial peptides isolated from green coconut water. *Peptides* 30, 633-637.
- Ghosh, K., Chandra, K., Ojha, A. K., Sarkar, S., and Islam, S. S. (2009). Structural identification and cytotoxic activity of a polysaccharide from the fruits of *Lagenaria siceraria* (Lau). *Carbohydr Res* 344, 693-98.

SIDDIK SARKAR

Durgapur, Daral hat, Dist: Dakshin Dinajpur, West Bengal , PIN-733127
Mobile: +91-9474333344, E-mail: siddikiitkgp@gmail.com

- Sarkar, S., Rajput, S., Tripathi, A., and Mandal, M. ZD6474 enhances the antiproliferative and apoptotic effects of UV-B radiation in breast carcinoma cells. *Int J Radiat Biol.* (Communicated)
- Sarkar, S., Bera, R. K., Rajput, S., Raj, C.R., and Mandal, M. Preparation and characterization of gold nanoparticle used in ZD6474 delivery in breast cancer. *Int J Pharm.* (Communicated)
- Sethi, K., Sarkar, S., Mohanty, B., and Mandal, M. (2011). Expressions of CK-19, NF- κ B, E-Cadherin, β -Catenin and EGFR as Diagnostic and Prognostic Markers by Immunohistochemical Analysis in Thyroid Carcinoma. *J Exp Ther Oncol.* (Accepted)
- Thakur, G., Mitra, A., Rousseau, D., Basak, A., Sarkar, S., and Pal, K. (2011). Crosslinking of gelatin-based drug carriers by genipin induces changes in drug kinetic profiles in vitro. *J Mater Sci Mater Med* 22(1), 115-23.
- Dash R, Azab B, Shen XN, Sokhi UK, Sarkar S, Su ZZ, Wang XY, Claudio PP, Dent P, Dmitriev IP, Curiel DT, Grant S, Sarkar D, Fisher PB (2011). Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. *Discov Med* 11(56), 46-56.